Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of rentosertib in idiopathic pulmonary fibrosis
CTR20262475Phase 3Active
- Sponsor
- Insilico Medicine
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of INS018_055 in idiopathic pulmonary fibrosis (IPF), sponsored by Insilico Medicine. Started Jun 2026; status: active.
02
Drugs
INS018_055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20262475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262475.